Please turn JavaScript on
European Biotechnology Magazine icon

European Biotechnology Magazine

Subscribe to European Biotechnology Magazine’s news feed.

Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.

Website title: European Biotechnology Magazine

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.21 / day

Message History

Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.

The post Ona Therapeutics bags $86.6m Series B for ...


Read full story

Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.

The post Ingenix raises €13m to scale AI drug dev...


Read full story

3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.

The post


Read full story

London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.

The post


Read full story

Parisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.

The post


Read full story